NMS·Healthcare·$74M·#390 / 520 in Healthcare
MCRB Seres Therapeutics, Inc.
29HIGH RISK
CATEGORY BREAKDOWN
GROWTH0
QUALITY0
STABILITY67
VALUATION0
GOVERNANCE59
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
N/A
0
> 50% strong
Gross Margin
Revenue retained after direct costs
-729.4%
0
> 50% strong
Cash Runway
Months of cash at current burn rate
999 months
100
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
187.6%
0
< 25% strong
Price / Sales
Market cap relative to trailing revenue
94.2x
0
< 3x strong
Rule of 40
Growth rate plus operating margin
N/A
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
11.8%
69
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+10.3%
39
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE MCRB WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when MCRB's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.